BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15705137)

  • 41. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
    Qiu L; Chen Y; Wu J
    Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type.
    Liu C; Zhang Y; Zhang Y; Wang M; Liu R; Liu X; Hu S
    Nucl Med Commun; 2016 May; 37(5):446-52. PubMed ID: 26657218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
    Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
    J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
    Kumar R; Xiu Y; Zhuang HM; Alavi A
    Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Imaging: staging and evaluation of lymphoma using nuclear medicine.
    Divgi C
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S11-8. PubMed ID: 15786021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Positron emission tomography in the evaluation of lymphoma.
    Israel O; Keidar Z; Bar-Shalom R
    Semin Nucl Med; 2004 Jul; 34(3):166-79. PubMed ID: 15202099
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients.
    Miller E; Metser U; Avrahami G; Dvir R; Valdman D; Sira LB; Sayar D; Burstein Y; Toren A; Yaniv I; Even-Sapir E
    J Comput Assist Tomogr; 2006; 30(4):689-94. PubMed ID: 16845304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).
    Jerusalem G; Beguin Y; Najjar F; Hustinx R; Fassotte MF; Rigo P; Fillet G
    Ann Oncol; 2001 Jun; 12(6):825-30. PubMed ID: 11484959
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
    Gill S; Wolf M; Prince HM; Januszewicz H; Ritchie D; Hicks RJ; Seymour JF
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):159-65. PubMed ID: 18650179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma.
    Even-Sapir E; Israel O
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S65-81. PubMed ID: 12644887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography.
    Kostakoglu L; Goldsmith SJ
    Clin Lymphoma; 2000 Jun; 1(1):67-74; discussion 75-6. PubMed ID: 11707816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma.
    Isasi CR; Lu P; Blaufox MD
    Cancer; 2005 Sep; 104(5):1066-74. PubMed ID: 16047335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience.
    Zanni M; Moulin-Romsee G; Servois V; Validire P; Bénamor M; Plancher C; Rouic LL; Dendale R; Vincent-Salomon A; Asselain B; Sahli R; Decaudin D
    Hematology; 2012 Mar; 17(2):76-84. PubMed ID: 22664045
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positron emission tomography scanning in the assessment of patients with lymphoma.
    Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
    Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
    Bar-Shalom R
    Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron emission tomography and gallium metabolic imaging in lymphoma.
    Coiffier B
    Curr Oncol Rep; 2001 May; 3(3):266-70. PubMed ID: 11296138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [18F-FDG PET/CT in lymphomas: assessment difficulties due to illness characteristics, and comparison with literature data].
    Garai I; Borbély K; Barna S; Szûcs B; Hascsi Z; Tóth Z; Illés A
    Magy Onkol; 2011 Sep; 55(3):178-86. PubMed ID: 21918743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.